Drug · CHEMBL6
INDOMETHACIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. INDOMETHACIN. Drugs and targets, record CHEMBL6. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL6
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Artracin, Artracin sr, Berlind 75 ret, Flexin-25 continus, Flexin-50 continus, Flexin-75 continus, Imbrilon, Indo-lemmon, Indo-paed, Indocid ret, Indocid-r, Indocin, Indocin sr, Indoderm, Indoflex, Indolar, Indolar sr, Indomax-25, Indomax-75 sr, Indomod, Indoptol, Indotard mr 75, Ledmecin, Maximet sr, Mobilan, Pardelprin mr, Rheumacin la, Rimacid, Slo-indo, Tivorbex
- ChEMBL
- Other names
- Aconip, Durametacin, Indometacin, Indometacin farnesil, Indometacina, Indometacine, Indometacinum, NSC-757061, NSC-77541, Reumacide
- ChEMBL
- Open Targets' highest stage
- Approval, for 12 of its 48 diseases, from ATC, DailyMed and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| PTGS1 | Cyclooxygenase | Cyclooxygenase inhibitor | INHIBITOR | https://conductscience.org/library/genes/5742 |
| PTGS2 | Cyclooxygenase | Cyclooxygenase inhibitor | INHIBITOR | https://conductscience.org/library/genes/5743 |
Source ChEMBL
Diseases48
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 48Source Open Targets
See all 48 diseasesTrials147
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT02002650 | Rectal Indomethacin to Prevent Post-ERCP Pancreatitis | 2,600 | 2016-05-27 | indomethacin | Its name | ClinicalTrials.gov | |
| NCT02797067 | Rectal Indomethacin to Prevent Post ESWL-pancreatitis | Phase 4 | 1,370 | 2022-05-26 | indomethacin | Its name | ClinicalTrials.gov |
| NCT01912716 | Rectal Indomethacin in the Prevention of Post-ERCP Pancreatitis | Phase 2/3 | 1,037 | 2019-06-18 | indomethacin | Its name | ClinicalTrials.gov |
| NCT02116309 | Randomized Trial of Rectal Indomethacin and Papillary Spray of Epinephrine Versus Rectal Indomethacin to Prevent Post-ERCP Pancreatitis | 948 | 2017-11-01 | indomethacin | Its name | ClinicalTrials.gov | |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity | Phase 3 | 928 | 2022-08-19 | indomethacin | Its name | ClinicalTrials.gov |
| NCT00033917 | Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial | Phase 3 | 630 | 2013-03-28 | indomethacin | Its name | ClinicalTrials.gov |
| NCT00820612 | Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients | Phase 4 | 602 | 2013-02-12 | indomethacin | Its name | ClinicalTrials.gov |
| NCT01543685 | Study of Indomethacin Capsules to Treat Pain Following Bunionectomy | Phase 3 | 462 | 2013-12-19 | indomethacin | Its name | ClinicalTrials.gov |
| NCT01774604 | Rectal Indomethacin to Prevent Post-Endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis | Phase 3 | 449 | 2016-09-20 | indomethacin | Its name | ClinicalTrials.gov |
| NCT00549549 | Celebrex In Acute Gouty Arthritis Study | Phase 3 | 402 | 2011-02-24 | indomethacin | Its name | ClinicalTrials.gov |
1 to 10 of 147
See all 147 trialsComparisons in its trials75
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Pre-ERCP Group vs Post-ERCP Group: Moderate-to-severe Pancreatitis | 11 of 1,297 | 23 of 1,303 | 2,600 | NCT02002650 | Trial comparisons |
| Pre-ERCP Group vs Post-ERCP Group: Post-ERCP Pancreatitis | 47 of 1,297 | 100 of 1,303 | 2,600 | NCT02002650 | Trial comparisons |
| Pre-ERCP Group vs Post-ERCP Group: serious adverse events | 15 of 1,297 | 15 of 1,303 | 2,600 | NCT02002650 | Trial comparisons |
| Indomethacin vs Glycerin: the Incidence of Post-ESWL Pancreatitis | 60 of 685 | 84 of 685 | 1,370 | NCT02797067 | Trial comparisons |
| Indomethacin vs Glycerin: deaths from any cause | 0 of 685 | 0 of 685 | 1,370 | NCT02797067 | Trial comparisons |
| Indomethacin vs Glycerin: serious adverse events | 0 of 685 | 0 of 685 | 1,370 | NCT02797067 | Trial comparisons |
| Standard Dose 100 mg vs High Dose 200mg: Number of Participants With Moderate or Severe Post-ERCP Pancreatitis | 28 of 515 | 28 of 522 | 1,037 | NCT01912716 | Trial comparisons |
| Standard-dose Indomethacin vs High-dose Indomethacin: deaths from any cause | 0 of 515 | 0 of 522 | 1,037 | NCT01912716 | Trial comparisons |
| Standard 100mg Dose vs High Dose 200 mg: Number of Participants Who Developed Post-ERCP Pancreatitis | 76 of 515 | 65 of 522 | 1,037 | NCT01912716 | Trial comparisons |
| Standard-dose Indomethacin vs High-dose Indomethacin: serious adverse events | 83 of 515 | 77 of 522 | 1,037 | NCT01912716 | Trial comparisons |
1 to 10 of 75
See all 75 comparisons in its trialsPapers from its trials124
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials5
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Vocabulary Test | 2 | 0 | ConductCognition |
| Dimensional Change Card Sort | 1 | 0 | ConductCognition |
| Eriksen Flanker Task | 1 | 0 | ConductCognition |
| Pattern and Letter Comparison | 1 | 0 | ConductCognition |
| Size Order Memory Test | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL6
GET https://conductscience.org/api/drugs/v1/CHEMBL6/diseases?page=2